LAURUS Labs
Chemistry for Better Living

Press Release

FOR IMMEDIATE RELEASE

29 October 2026

Laurus Labs invests in Galenvs Sciences for a majority ownership, to strengthen capabilities in TIDES therapeutics & CDMO Services

Hyderabad, October 29, 2026: Laurus Labs Ltd. (**Laurus BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01028**), a leading research-driven pharmaceutical and biotechnology company, today announced signing of a definite agreement for investments in to Galenvs Sciences for a majority ownership, a Montréal, Québec, Canada-based biotechnology company specialising in precision magnetic nanoparticles and DNA/RNA technologies for advanced diagnostics and therapeutics. This marks an important step in Laurus Labs' strategy to strengthen its capabilities in oligonucleotide development and manufacturing, while enhancing its Contract Development and Manufacturing Organization (CDMO) offerings.

The strategic investment is aimed at unlocking greater efficiency, scalability and technological capabilities in RNA and oligonucleotide manufacturing, enabling Laurus Labs to expand its presence in the rapidly growing field of DNA/RNA-based precision therapeutics. The combination of Galenvs Sciences' specialised technology platforms with Laurus Labs' research, development and manufacturing capabilities is expected to create differentiated solutions for customers developing complex and next-generation therapeutics.

The signing of a definitive Term sheet Agreement on 29th October 2026, under which Laurus Labs Ltd. acquiring 60% of the equity share capital, at a pre money valuation of USD 3.50 million subject to due diligence. Laurus Labs propose to invest 3.75 million, which includes a primary infusion of USD 2.75 million.

Dr. Satyanarayana Chava, Founder & Chief Executive Officer, Laurus Labs said, *"The investment in to Galenvs Sciences marks another pivotal step in Laurus Labs' strategic evolution as a research-driven organization that has consistently invested ahead of the curve. Galenvs brings differentiated technology capabilities in oligonucleotides and precision magnetic nanoparticles, which we believe can create significant value for our customers and strengthen our capabilities in TIDES. By combining these technologies with our research, development and manufacturing strengths, we aim to enable the development of advanced therapeutics more efficiently and at scale. Our objective is to build differentiated capabilities that can help bring next-generation therapies to patients at an affordable cost, while creating long-term value for our customers and stakeholders."*

The investment in Galenvs by Laurus Labs brings together complementary capabilities in end-to-end capabilities in Oligonucleotide segment from early-stage oligonucleotide process

Corporate Office
Plot No. 103, Road No.1, Jubilee Hills, Hyderabad 500033, Telangana, India
T +91 40 6659 4333, 2342 0500/501 **F** +91 40 6659 4320

Registered Office
Laurus Enclave, Plot Office 01, E.Bonangi Village, Parawada Mandal, Anakapalli District – 531021, Andra Pradesh, India
CIN : L24239AP2005PLC047518, **T** +91 891 682 1101, 1102, **F** +91 891 682 1103, E info@lauruslabs.com, **W** lauruslabs.com

development, conjugation and advanced purification technology including fill finish. Laurus expertise in Large-scale manufacturing involving complex chemistry, fermentation, peptide development and manufacturing, analytical science, drug product formulation and sterile fill & finish will offer a seamless journey for partners in Oligonucleotides. Laurus and Galenvs would expand scientific talent in Montreal and manufacturing infrastructure in India.

Commenting on the acquisition, **Dr. Jamal Daoud, Founder & Chief Executive Officer**, **Galenvs Sciences** said, *"We are excited to partner with Laurus Labs at an important stage in Galenvs' growth. Combining our oligonucleotide development and magnetic nanoparticle capabilities with Laurus' extensive development and manufacturing infrastructure creates a strong platform to serve customers from early-stage development through scale-up and manufacturing. We look forward to growing our scientific capabilities in Montréal while building a broader global offering together."*

Following this, Galenvs Sciences', will continue under the ownership of Laurus Labs, with a focus on preserving its scientific capabilities, technological expertise and customer-centric approach. The integration is expected to provide opportunities to leverage complementary strengths and expand the range of solutions offered to customers globally.

END

Investors Relations	Media Relations
Vivek Kumar T +91 40 3980 4366 investorrelations@laburslabs.com	Karthik C T +91 40 3980 4380 | 9030088669 mediarelations@laburslabs.com

About Laurus Labs

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions.

The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its "Smart and Green" chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a "BBB" MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices.

Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle "Chemistry for Better Living," Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

About Galenvs Sciences

Galenvs Sciences Inc. is a Montréal, Québec-based contract research and development organization (CRO/CDMO) specializing in oligonucleotide technologies and functional magnetic nanoparticles for diagnostic and therapeutic applications. The company supports customers across development, synthesis, purification, analytical testing and pilot-scale production, with a focus on building scalable technologies for advanced diagnostics and next-generation therapeutics.

For more information visit **www.lauruslabs.com**

Follow @ Laurus Labs on **LinkedIn** | **Twitter** | **Facebook** | **Instagram**

Disclaimer

Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.